meta
|
evidence
oncology
Living systematic review and meta-analysis
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
1
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)
immune chekpoint inhibitors
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs non active control
vs no additional treatment
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
progression or deaths (PFS)
AE (grade 3-4)
AE leading to death (grade 5)
deaths (OS)
limited stage SCLC (ls-SCLC) - maintenance (M)
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
versus no additional treatment
nivolumab plus ipilimumab vs. no additional treatment
1
certainty unassessable
-5%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open